PeriodontalDisease Therapeutics Market by Drug Type (Arestin, Atridox, Doxycycline,Metronidazole, Minocycline, Periochip, and Others), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Online) - Size, Share, Outlooks,and Opportunity Analysis 2018 - 2026
Periodontitis is a chronicbacterial infection caused by microbial plaque often known as gum disease thatis colonized on tooth surface and below the gingival margin. It involvesprogressive loss of the alveolar bone, which is a thickened ridge of bone thatcontains tooth socket over the bones that holds teeth. According to NationalInstitutes of Health 2017, around 20-15% of global population is estimated to sufferfrom severe periodontitis in comparison to 5-10% in 2004, which is propellingdemand for its diagnosis and treatment worldwide in the medical industry.
In periodontitis, gums are pulledaway from teeth and form spaces (pockets), which are prone to get infected. Ifsuch infection is untreated, it can lead to increase periodontal pocket lengthand bleeding on probe, in turn leading to the alveolar bone loss and teethloss. In order to complement a non-surgical therapy in periodontitis multipleantimicrobial options are available, such as metronidazole, chlorhexidine,minocycline, doxycycline, tetracycline, which can be locally delivered tomucosa. These drugs are used to inhibit periodontopathogenic microorganism aswell as modulate the inflammatory response of tissues.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2022
Periodontal Disease TherapeuticsMarket Drivers
Oral care and dental hygiene areone of the major concerns worldwide. High prevalence of periodontal disease ispropelling demand for oral treatment. Periodontal disease is a result of variousrisk factors, such as aging, smoking, poor oral hygiene, heredity, stress, andother medical conditions.
Periodontal disease are majorlyobserved in adults. According to the Centre for Disease Control and Prevention(CDC), in 2018, the prevalence of periodontitis has been estimated to be over50% in U.S. adults aged 30 years and older i.e. 64.7 million Americans. Amongthose adults, 8.7% showed mild disease, 30% demonstrated moderate disease, 8.5%had severe chronic periodontitis. Disease prevalence increases with age, with70% adults, who are 65 years and above, suffering from periodontitis. There aremany environmental risk factors that are associated with inflammatoryresponses, which include smoking, diabetes mellitus, and poor health habits drivingthe chronic inflammatory response in periodontitis, and are beneficial for theperiodontitis disease therapeutic market.
Also, advancements in treatmentby using novel drugs is expected to fuel the periodontal disease therapeuticsmarket growth. For instance, in January 2017, ST266 by Noveome Biotherapeutics,Inc., is an expected candidate for disease treatment, which is currently inphase I clinical trials. ST266, is used to treat patients with moderate tosevere periodontitis. It provide essential tools at critical stages of thehealing process to restore homeostasis within the periodontalmicroenvironment.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/periodontal-disease-therapeutics-market-2022
Local antibiotics for thetreatment of periodontal disease to present more growth opportunities in theperiodontal disease therapeutics market. Increasing preference for controlledlocal drug delivery approaches over systemic drug delivery due to bettertherapeutic outcomes by achieving factors such as site specific delivery, lowdose requirement, reduces side effects favors the growth of local antibiotics.Furthermore, it provide safe and effective mode of treatment and is expected tolead the market in the next few years due to various advantages. Systemicantibiotics is expected to hold dominance in global market due to factors suchas product affordability, availability, and high market penetration. Growingnumber of preventive care for dental and gum problems and poor reimbursementpolicies in many economies are hindering the growth of periodontal diseasetherapeutic market.
Periodontal Disease TherapeuticsMarket Regional Analysis
Based on geography, North Americadominated the periodontal disease therapeutics market due to high awareness ofperiodontal disease. High prevalence of periodontal disease due to desk boundor seated lifestyle, efficient reimbursements, and drug abuse. Also, increasedhealthcare spending has contributed to growth of market. For instance, in theU.S., according to the Centers for Medicare and Medicaid Services (CMS)spending for dental services increased by 4.6% in 2016, to US $124.4 Bn, aslight acceleration from 4.4% in growth in 2015. Furthermore, Asia Pacific isexpected as an emerging lucrative market for periodontal therapeutics marketdue to large patient pool, growing healthcare infrastructure, and expenditure.Also, investments into research and development for more effective therapies byprominent players in the region drives the periodontal disease therapeuticsmarket.
Periodontal Disease TherapeuticsMarket Competitor Analysis
Key players in operating in theperiodontal disease therapeutic market include DenMat Holdings LLC., 3M,Valeant Pharmaceuticals International, Inc., Galderma S.A., Dexcel Pharma Ltd.,Kaken Pharmaceutical Co., Ltd., and OraPharma Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2022
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
